查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023年至2028年Kifoplasty市场预测
市场调查报告书
商品编码
1410143

2023年至2028年Kifoplasty市场预测

Kyphoplasty Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021 年 Kifoplasty 市值为 799,574,000 美元，预计到 2028 年将以 5.48% 的复合年增长率增长至 1,161,548,000 美元。

Kifoplasty 是一种用于缓解脊椎压迫性骨折引起的疼痛的医疗程序。当全部或部分脊椎塌陷时，就会发生这些骨折，导致不适和脊椎稳定性下降。透过接受 Kifoplasty，患者可以缓解疼痛并改善脊椎功能。 Kifoplasty 用于恢復脊椎排列和治疗椎骨骨折。 Kifoplasty 的最终用户包括医院、诊所和门诊手术中心。

医疗保健产业的成长推动了 Kifoplasty 市场的成长

Kifoplasty 是一种安全有效的手术，用于治疗骨质疏鬆症或外伤等疾病引起的疼痛性椎体压迫性骨折。 Kifoplasty 提供了一种微创解决方案来稳定骨折的脊椎骨、恢復脊椎骨高度并缓解疼痛。透过政府措施扩大医疗保险和改善医疗服务的可近性正在促进整个医疗保健产业的成长和发展。

骨质疏鬆症盛行率的增加推动了 Kifoplasty 市场的扩张

Kifoplasty 用于治疗与骨质疏鬆症相关的椎体压迫性骨折。椎骨成形术是一种微创手术，涉及将球囊插入骨折的脊椎骨中并使其膨胀以形成空腔，然后注入骨水泥以稳定骨折并恢復脊椎骨的高度。骨质疏鬆症的增加主要是由于老化、久坐的生活方式以及钙和维生素D摄取不足等因素造成的。根据自然医学图书馆的数据，预计EU27+2地区每年骨质疏鬆性骨折的数量预计将从2019年的428万起大幅增加至106万起，到2034年总合达到505万起。

微创推动 Kifoplasty 市场成长

Kifoplasty 是治疗椎体骨折的传统手术方法的微创替代方案。这种治疗方法有几个优点，包括住院时间更短、恢復时间更快和术后併发症更少，使其成为对患者和医疗保健提供者都有吸引力的选择。由于整个过程通常需要不到一小时，Kifoplasty 是一种有吸引力的解决方案，可以有效解决脊椎相关问题、改善患者治疗效果并减轻医疗机构的负担。它是微创的，对于那些寻求破坏性较小且有效的治疗方法来治疗痛苦的椎骨骨折和脊椎后凸的人来说是首选。

预计北美将主导 Kifoplasty 市场

预计北美在 Kifoplasty 市场中占据重要份额的主要原因是创伤性脊椎损伤发生率的上升以及政府的投资和倡议。根据 2021 年国家脊髓损伤统计中心的数据，美国每年每百万人中约有 54 例创伤性脊髓损伤 (SCI)，导致每年约 18,000 例新增 SCI。这些数字突显了创伤性脊髓损伤对人群的重大影响，并强调了对 Kifoplasty 等有效治疗方法的需求。

与 Kifoplasty 相关的风险限制了 Kifoplasty 市场的成长。

与此手术相关的风险，例如感染、出血、背痛加剧以及神经损伤可能导致的麻木和虚弱，对整体市场成长构成了挑战。此外，对引导 X 射线中使用的化学物质的潜在过敏反应以及水泥从预定位置意外洩漏的风险的担忧也值得注意。这些风险阻止了一些患者选择 Kifoplasty，儘管它在治疗椎骨骨折和脊椎后凸方面已被证明有效，从而影响了市场成长。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章 Kifoplasty 市场：副产品

  • 介绍
  • 球囊导管
  • 骨骼接入装置
  • 水泥应用产品
  • 骨水泥
  • 水泥搅拌系统
  • 乐器

第六章 Kifoplasty 市场：依应用

  • 介绍
  • 修復脊椎骨排列
  • 椎骨骨折
  • 脊椎

第七章 Kifoplasty 市场：依最终用途

  • 介绍
  • 医院和诊所
  • 门诊手术中心

第八章 Kifoplasty 市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Stryker
  • Medtronic Inc.
  • MicroPort Scientific Corporation
  • DePuy Synthes（Johnson & Johnson Services Inc.）
  • IZI Medical Products
  • Merit Medical Systems
  • Joimax GmbH
  • G21 Srl
  • Joline GmbH & Co. KG
  • Hensler Surgical Products
简介目录
Product Code: KSI061615817

The kyphoplasty market was evaluated at US$799.574 million in 2021 and will grow at a CAGR of 5.48% to be worth US$1,161.548 million by 2028.

Kyphoplasty is a medical procedure employed to alleviate pain caused by compression fractures in the spine. These fractures occur when all or a portion of a spine bone collapses, leading to discomfort and reduced spinal stability. By undergoing kyphoplasty, patients can experience relief from pain and improved spinal function. Kyphoplasty finds applications in the restoration of vertebral alignment and treatment of spinal fractures. The end users of kyphoplasty include hospitals & clinics as well as ambulatory surgical centers.

The rise in the healthcare sector bolsters the kyphoplasty market growth.

Kyphoplasty is a safe and effective procedure to treat painful vertebral compression fractures caused by conditions like osteoporosis and traumatic injuries. These fractures often result in severe pain and reduced mobility, and kyphoplasty offers a minimally invasive solution to stabilize the fractured vertebrae, restore vertebral height, and alleviate pain. The expansion of healthcare coverage and improved access to medical services driven by government initiatives contribute to the overall growth and development of the healthcare industry. For instance, in March 2022, Spine BioPharma secured a significant $14 million series B round of funding, earmarked to bolster its injectable treatment for degenerative disc disease.

Increasing prevalence of osteoporosis drives the kyphoplasty market expansion.

Kyphoplasty is used as a treatment for osteoporosis-related vertebral compression fractures, which occur due to weakened bones in individuals with osteoporosis. In kyphoplasty, a minimally invasive procedure, a balloon is inserted into the fractured vertebra and inflated to create a cavity, followed by the injection of bone cement to stabilize the fracture and restore vertebral height. Osteoporosis is increasing primarily due to factors such as an aging population, sedentary lifestyles, and inadequate calcium and vitamin D intake. According to the Natural Library of Medicine, the projected annual number of osteoporotic fractures in the EU27+2 region is anticipated to rise significantly by 1.06 million, reaching a total of 5.05 million cases in 2034, compared to 4.28 million cases in 2019.

Minimally invasive nature drives kyphoplasty market growth.

Kyphoplasty stands out as a less invasive alternative to conventional surgical methods for treating vertebral fractures. This procedure offers several advantages, including shorter hospital stays, quicker recovery times, and fewer post-operative complications, making it a compelling choice for patients and healthcare providers alike. With the entire process typically taking less than an hour, kyphoplasty presents an appealing solution for effectively addressing spine-related issues, improving patient outcomes, and reducing the burden on healthcare facilities. Its minimally invasive nature makes it a favorable option for those seeking a less disruptive and more efficient treatment approach for painful vertebral fractures and kyphosis.

North America is expected to dominate the kyphoplasty market.

North America is projected to hold a significant share of the kyphoplasty market primarily due to the escalating incidence of traumatic spinal injuries coupled with government investments and initiatives. For instance, in January 2022, under the leadership of UBC researchers, a groundbreaking project with funding of $24 million had been initiated to advance the treatment of spinal cord injuries. Also, according to the National Spinal Cord Injury Statistical Center in 2021, the United States witnessed an annual incidence of approximately 54 cases of traumatic spinal cord injury (SCI) per one million people, resulting in approximately 18,000 new SCI cases each year. This figure highlights the significant impact of traumatic spinal cord injuries on the population, emphasizing the need for effective treatments like kyphoplasty.

Risks involved in kyphoplasty restrain the kyphoplasty market growth.

The risks associated with the procedure such as infection, bleeding, increased back pain, and the possibility of numbness, or weakness due to nerve damage are posing a challenge to the overall market growth. Moreover, there are notable concerns regarding potential allergic reactions to chemicals utilized with X-rays for guidance and the risk of unintended cement leakage from its intended position. These risks may deter some patients from opting for kyphoplasty, impacting market growth despite its proven effectiveness in treating vertebral fractures and kyphosis.

Key Developments

  • August 2021: IZI Medical launched Vertefix HV Cement, providing physicians with an advanced solution to monitor and regulate the flow of cement during vertebroplasty and kyphoplasty procedures. This innovative product incorporates variable-sized barium particles with high viscosity, enabling precise tracking and control of cement distribution. As a result, Vertefix HV Cement significantly enhances procedural outcomes and ensures greater safety for patients, making it a valuable addition to the medical community's arsenal in treating related conditions effectively and with improved precision.
  • May 2020: Medtronic plc introduced the Kyphon Assist Directional Cannula in the United States, complementing its balloon kyphoplasty (BKP) products to address vertebral compression fractures arising from osteoporosis, cancer, or benign lesions. This novel device empowers physicians with enhanced control during bone tamp inflation and height restoration compared to conventional balloon kyphoplasty cannulas. The Kyphon Assist Directional Cannula represents a significant advancement in the treatment of vertebral fractures, enabling more precise and effective procedures for those suffering from these conditions.

Company Products

  • AVAflex Balloon System: Stryker's AVAflex balloon system offers a simplified and effective approach to treating vertebral compression fractures (VCFs) while achieving bipedicular results with a unipedicular approach. With its multiple balloon sizes and needle gauge options, AVAflex is designed to cater to various physician preferences and patient requirements. The system's curved coaxial needle allows for precise cement placement, ensuring an optimal fill within the vertebral body. With these advanced features, AVAflex empowers healthcare professionals to streamline VCF treatments, providing targeted and efficient solutions for improved patient outcomes.
  • KYPHON BALLOON KYPHOPLASTY PLATFORM: Medtronic's Kyphon is a groundbreaking innovation, offering several advantages over previous technologies. With a maximum rated inflation pressure of 700 psi, the balloons provide higher pressure capabilities compared to the previous 400 psi balloons. The cement resistance technique enables physicians to deliver cement through one cannula while maintaining fracture reduction by keeping the contralateral balloon inflated. Additionally, the Kyphon cement delivery system allows for cement delivery from up to 48 inches away from the radiation source during a kyphoplasty procedure.

Segmentation

By Product

  • Balloon Catheters
  • Bone Access Devices
  • Cement Application Products
  • Bone Cement
  • Cement Mixing Systems
  • Instruments

By Application

  • Vertebral Alignment Restoration
  • Spinal Fractures
  • Kyphosis

By End-Use

  • Hospitals & Clinics
  • Ambulatory Surgical Centers

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. KYPHOPLASTY MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Balloon Catheters
  • 5.3. Bone Access Devices
  • 5.4. Cement Application Products
  • 5.5. Bone Cement
  • 5.6. Cement Mixing Systems
  • 5.7. Instruments

6. KYPHOPLASTY MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Vertebral Alignment Restoration
  • 6.3. Spinal Fractures
  • 6.4. Kyphosis

7. KYPHOPLASTY MARKET, BY END-USE

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Ambulatory Surgical Centers

8. KYPHOPLASTY MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Stryker
  • 10.2. Medtronic Inc.
  • 10.3. MicroPort Scientific Corporation
  • 10.4. DePuy Synthes (Johnson & Johnson Services Inc.)
  • 10.5. IZI Medical Products
  • 10.6. Merit Medical Systems
  • 10.7. Joimax GmbH
  • 10.8. G21 S.r.l.
  • 10.9. Joline GmbH & Co. KG
  • 10.10. Hensler Surgical Products